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Abstract 
Introduction: The soaring incidence of gout in the United Kingdom suggests that medical 
practitioners should be increasingly aware of optimizing management of gout, which is aimed at 
pain relief, preservation of joint function and preventing recurrent attacks. Recent guidelines 
published by the British Society of Rheumatology (BSR), have provided clinicians with a 
framework for achieving these aims.  
Aims: To evaluate the management of gout in a primary care centre in North West England 
against recognized standards.  
Methods: An electronic search on EMIS Web using the Read codes “gout” and “gouty 
arthritis”, with a specified period of 2010–2013, generated a cohort of patients who were 
categorized into 2 groups: those prescribed urate-lowering therapy (allopurinol) and those not. 
Patients on febuxostat were excluded. Clinical data from the patients were extracted and 
retrospectively audited.  
Results: A total of 112 patients were identified, of which only 46% (n = 52) of patients were 
reviewed after an acute attack. Among those who were prescribed allopurinol, only 19% (n = 12) 
achieved target serum urate levels while only 67% (n = 42) had their serum urate levels checked 
regularly and 31% (n = 20) had dosage adjustments. Comparatively, in patients not prescribed 
allopurinol, a few indications for initiating allopurinol were detected: 29% (n = 12) had more 
than one attack of gout in a year, 27% (n = 11) suffered from renal insufficiency, 2% (n = 1) 
presented with tophi, and 17% (n = 7) were on diuretics. 
Conclusion: Gout management in this primary care centre is not fully concordant to the BSR 
guidelines. Clearly, there is a need to improve adherence, particularly in the tight monitoring of 
serum uric acid levels, medications review, appropriate use of allopurinol, where indicated, and 
patient follow-up. 
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The Management of Gout in 
Primary Care – Are We Doing it 
Right?  
Introduction 
Gout, a disorder of purine metabolism, is 
characterized by hyperuricaemia and leads to 
deposition of uric acid crystals in joints, 
precipitating acute inflammatory arthritis, 
tophi around joints, and uric acid urolithiasis. 
Gout has become the most common 
inflammatory arthritis, affecting 2.49% of the 
population.1,2 Over the past 16 years, its 
incidence has increased rapidly in the United 
Kingdom, and tends to increase with age, 
especially afflicting those above 65 years.2,3 
Gout is more common in men, with an 
incidence of 4.42 per 1000 in men but 1.32 
per 1000 in women.4 
The short-term management of gout is 
centred on pain relief and preservation of 
joint function while long-term management 
targets prevention of recurrent attacks and 
chronic joint damage. Patients presenting with 
mild gout symptoms are treated by self care 
and lifestyle modification, but for those with 
moderate to severe attacks, the addition of 
medication to treat gout is pivotal.5 Medical 
treatment includes the usage of non-steroidal 
anti-inflammatory drugs (NSAIDs), colchicine, 
and corticosteroids. Where indicated, the 
recurrence of gout is controlled by initiating 
urate-lowering therapy (ULT) (e.g. 
allopurinol), which decreases the level of uric 
acid in the blood. Therefore, patients have 
their serum uric acid (sUA) levels monitored 
regularly and doses of allopurinol are titrated 
appropriately until the target urate level is 
achieved. 
A recent British Medical Journal publication 
revealed that the clinical management of gout 
in primary care has not improved over the 
years and remains suboptimal.6 With the 
increasing prevalence of gout, the expected 
number of patients being treated with ULT 
should increase. However, this has remained 
stagnant, at just a third of the gout 
population.2,6 A series of guidelines in the 
management of gout has been established by 
the European League Against Rheumatism 
(EULAR), British Society of Rheumatology 
(BSR), and American College of 
Rheumatology (ACR) between 2006 and 2012, 
which emphasizes the importance of titrating 
urate-lowering therapy to achieve a serum 
urate target below 300–360 μmol/L.7-9 
Aims & Standards 
Aims 
To assess whether patients with gout have 
been appropriately managed and monitored 
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according to the BSR guidelines in a GP 
practice in north-west England. 
Standards 
1. 100% of patients who have been diagnosed 
with gout should have their serum uric acid 
checked after 4–6 weeks of an acute attack.  
2. 90% (to allow for patient choice) of chronic 
gout patients (patients with > 2 episodes of 
gout in a year who were started on allopurinol) 
should: 
 Have sUA levels tested since initiation 
of allopurinol 
 Have allopurinol dosages reviewed 
based on sUA 
 Achieve a sUA of < 300 μmol/L 
 
3. 90% (to allow for patient choice and 
contraindications) of patients should start 
allopurinol if they: 
 Had > 1 attack of gout 
 Have renal insufficiency  
 Have tophi 
 Have uric acid stones 
 Are on diuretics 
 
 
 
 
 
 
Methods 
Inclusion criteria 
All adult patients registered with the practice 
with a Read-coded diagnosis of gout in their 
medical records from 2010 to 2013 were 
included in the audit. In UK general practices, 
Read codes are commonly used to record 
patients’ comorbidity types, processes of care, 
and administrative information.  
Patients who were on febuxostat (which is 
deemed an alternative to allopurinol) were 
excluded from Standard 2 as febuxostat was 
recently approved as a ULT but was not 
included into the BSR guidelines at the time 
of its publication.10 Table 1 outlines the 
criteria involved in reference to the guideline 
published by the BSR.7 
Search strategy 
This audit was undertaken at a GP surgery in 
a suburban town in Greater Manchester. 
Using the electronic patient database (EMIS 
Web) from the GP practice, a search was 
carried out to identify all patients who had a 
Read-coded diagnosis of “gout” and/or 
“gouty arthritis” between 1 January 2010 and 
31 December 2013. The electronic records of 
all relevant patients were searched and notes 
were individually analysed based on the 
template in Figure 1.7 
Res Medica 2014, Volume 22, Issue 1                              
Lim ELP. & Tan TSE. The Management of Gout in Primary Care – Are We Doing it Right? Res Medica 2014, 22(1), pp.102-110. 
doi:10.2218/resmedica.v22i1.822. 
104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Audit criteria based on BSR guidelines7 
 
Theme Guideline Criteria 
Assessment of gout 
patients 
All patients presenting with acute 
gout should have their serum 
urate checked after 4-6 weeks 
-Patient recorded sUA 4-6 weeks after diagnosis 
of gout 
Management and 
monitoring of chronic 
gout 
Allopurinol prescribed and 
titrated until 
sUA<300micromol/l 
 
-Patients having sUA levels tested since initiation 
of medication 
-Patients having allopurinol dosage reviewed 
based on sUA 
-Patients having sUA<300micromol/l 
Indications of allopurinol Allopurinol is started in patients 
with second attack within a year, 
renal insufficiency, tophi, uric 
acid stones and continuing 
treatment on diuretics 
-Patient with:  
 >1 attack of gout in a year  
 renal insufficiency 
 tophi 
 uric acid stones 
 continuous treatment of diuretics  
            not on allopurinol 
7 
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Results 
A total of 112 patients with a diagnosis of 
gout were identified. See Table 4 for a 
summary of the audit results.  
Demographics 
Out of the 112 patients with gout, 87 patients 
(78%) were male and 25 patients (22%) were 
female (Figure 2). The patients’ ages ranged 
from 27 to 94 years.  
Figure 2. Gender distribution of gout patients 
 
Assessment of gout patients 
All the patients were included to determine 
whether they had a 4–6 week review checking 
sUA. A total of 52 patients (46%) received 
appropriate review (Figure 3).  
Figure 3. Patients reviewed within 4-6 weeks. 
 
 
Acute management of gout 
71 patients (63%) were treated with NSAIDs, 
19 patients (17%) with colchicine, 2 patients 
(2%) with corticosteroids, and 20 patients 
(18%) were not treated with medication 
(Figure 4). 
Figure 4. Types of treatment for acute gout 
Management of chronic gout 
68 patients (61%) were recorded to be using 
ULT and 44 patients (39%) were not. Of 
those receiving ULT, 5 were excluded for 
using febuxostat while 3 others were not on 
ULT due to personal choice. Therefore, after 
correction, 104 patients were identified to be 
either on allopurinol (63 patients [61%]) or 
not (41 patients [39%]) (Figure 5).  
Figure 5. Usage of allopurinol
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Monitoring of chronic gout 
Among those on allopurinol, 42 patients (67%) 
had their sUA checked monthly while 21 
patients (33%) did not. Dose adjustments of 
allopurinol had been made in 20 patients 
(31%). 12 patients (19%) managed to achieve 
the target value sUA level of <300 μmol/L 
(Table 2). 
Table 2. Findings of patients on allopurinol 
 
Indications of allopurinol  
As for patients not on allopurinol, 12 (29%) 
had more than 1 episode of gout within a year, 
11 (27%) had renal impairment, 1 (2%) was 
found to have tophi, none had uric acid 
stones, and 7 (17%) were on diuretics. Of the 
41 patients not on allopurinol, 15 patients 
(37%) had their sUA checked while the other 
26 patients (63%) did not. Among the 15 
patients who had their sUA checked, 6 
patients (40%) had a sUA level <300 μmol/L 
(Table 3). 
Table 3. Findings of patients not on allopurinol 
 Yes No 
> 1 attack in a year 12 (29%) 29 (71%) 
Renal insufficiency 11 (27%) 32 (78%) 
Tophi 1 (2%) 40 (98%) 
Diuretics 7 (17%) 34 (83%) 
Checked sUA 15 (37%) 26 (63%) 
Uncontrolled sUA 9 (60%) 6 (40%) 
Table 4. Summary of audit results 
 
Discussion 
Despite the common occurrence of gout, 
affecting every 1 in 40 people, the 
management of gout in primary care is 
generally poor.2,6 The results of this audit 
elucidated the pitfalls in the management of 
gout and has helped to identify areas for 
further improvement. A similar trend was 
demonstrated by an audit conducted in a 
primary care setting in North Staffordshire,9 
Standards Compliance 
1. 100% of patients who 
have been diagnosed with 
gout should have their 
serum uric acid checked 
after 4–6 weeks of an acute 
attack.  
46% (52/112) 
No patients were 
excluded 
2. 90% (to allow for patient 
choice) of chronic gout 
patients should: 
 
 Have sUA levels tested 
since initiation of 
allopurinol 
 Have allopurinol dosages 
reviewed based on sUA 
 Achieve a sUA of < 
300 μmol/L 
 
Only patients started on 
allopurinol 
 
 
 67% (42/63) 
 
 
 31% (20/63) 
 
 19% (12/63) 
3. 90% (to allow for patient 
choice and 
contraindications) of 
patients started with 
allopurinol if they: 
 
 Had > 1 attack of gout 
 Have renal insufficiency 
 Have tophi 
 Have uric acid stones 
 Are on diuretics 
  
Only patients not 
started on allopurinol 
(Number of patients 
who did not show 
indications were used) 
 
 71% (29/41) 
 73% (30/41) 
 98% (40/41) 
 100% (41/41) 
 83% (34/41) 
 Yes No 
Regular sUA checks 42 (67%) 21 (33%) 
Altered dosage based on 
sUA 
20 (31%) 43 (69%) 
Achieved target 
sUA<300micromol/l 
12 (19%) 51 (81%) 
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UK, which revealed that the management of 
gout did not fully comply with BSR guidelines.  
Our results revealed that many patients did 
not have a documented sUA level 4–6 weeks 
after an acute episode. Although sUA is not a 
diagnostic marker for gout, it serves to guide 
further management, especially in deciding 
whether or not to initiate ULT. 
In the aspect of managing acute gout, the 
practice in this audit appears to adhere to the 
guideline. As commonly practised, NSAIDs 
have been widely used for relieving joint pains 
and swellings rapidly, while colchicine and 
steroids are the next line of therapy if 
contraindications arise. A minority of patients 
were not being treated with medications but 
were only advised about lifestyle changes. 
Although this may help ease symptoms by 
reducing the intake of uric acid, acute gout is 
known to be the most painful form of 
arthritis, hence analgesics should be given in 
conjunction with lifestyle advice.1 
Since the 1970s, allopurinol has been the 
mainstay of chronic treatment.11 Our records 
show that only a handful of patients had their 
allopurinol dosages titrated against the sUA 
and had their sUA checked regularly. BSR 
guidelines for allopurinol administration 
recommend progressive dose titration from a 
starting dose of 50–100 mg daily with 
increments of 50–100 mg to a maximum dose 
of 900 mg daily until target sUA level is 
achieved.7 A clinical study of gout patients 
reported that 372 mg was the mean 
allopurinol dose that normalized sUA levels.12 
However, the common dosages of allopurinol 
prescribed in clinical practice are usually 
300 mg daily or less. Hence, a possible area of 
research would be in reviewing prescription 
dosages to determine the optimum dose for 
controlling sUA levels.  
As the target value has been set at a sUA of < 
300 μmol/L, expert consensus concurred that 
below this value the rate of crystal elimination 
is increased and the risk of developing tophi is 
reduced. In the study by Pascual and Sivera,13 
arthrocentesis was performed in 18 patients 
before initiation of ULT and it was found that 
crystals soon disappeared after a dramatic 
reduction of sUA. Although the current trend 
of “treating to target” is being emphasized, 
only a few have successfully achieved the 
goal.13 The findings also suggest that sUA 
measurements do not precipitate allopurinol 
titration. 
In patients who do not receive allopurinol, 
studies advocate offering allopurinol to 
patients with either a second episode of gout 
within a year, renal insufficiency, presence of 
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tophi, uric acid stones or persistent use of 
diuretics.  
Clearly, there is a need to improve the 
prescribing of allopurinol in our centre. Our 
results demonstrate that many of our patients 
with a history of more than 1 episode of gout 
within a year (one of the indications for 
initiating allopurinol) were not given 
allopurinol to control recurrence. Similarly, 
patients with renal insufficiency (who had 
their estimated glomerular filtration rate 
(eGFR) checked and were diagnosed with 
chronic kidney disease (CKD) of at least stage 
3A and above, predisposing them to 
hyperuricemia), patients with tophi, and 
patients on diuretics prescribed with either 
furosemide or bendroflumethiazide, were also 
found to have not been prescribed allopurinol. 
An audit in 2002 conducted by Roberts et al.14 
revealed that 86% of GPs claimed to be 
confident in managing gout patients. However, 
our audit results have shown that our primary 
care management of gout is inadequate due to 
poor adherence to the guidelines. To 
determine if this could be a nationwide 
primary care issue, multicentre audits are 
required. 
Table 5 summarizes the recommendations for 
change. We aim to re-audit this study in 2 
years’ time. 
Table 5. Recommendations of audit
Conclusion 
Issue Recommendations 
1. Patients not currently 
managed according to 
guidelines 
 Review gout patients – prescribe allopurinol as appropriate and check sUA levels 
in patients who have not had it  
 Review allopurinol prescriptions in line with sUA levels 
2. Lack of awareness of 
guidelines available 
 Involve GPs in national rheumatology conferences and encourage multicentre 
audits on management of gout  
 Discuss guidelines during practice meetings 
3. Varying assessment and 
targets in practice and a 
lack of a reminder 
system 
 Integrate a clinical template into electronic database, having system prompted 
disease-specific Read codes during consultations 
 Possible incorporation of gout management into the Quality and Outcomes 
Framework (QOF) 
4. Lack of medication 
review 
 Create reminders on the system for a medication review in line with sUA levels 
5. Lack of patient 
awareness 
Patient education: 
 Implementing posters in GP surgery waiting areas  
 Hand out leaflets to high-risk age groups 
6. Neglected advice on 
lifestyle changes 
 Provision of leaflets to encourage dietary changes and weight loss 
 Encourage a lifestyle diary 
 Encourage patients to connect with other patients with gout 
7. Patient compliance to 
medication 
 Ensure proper patient education regarding allopurinol before starting therapy 
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Primary care centres should be aware of the 
available guidelines for the appropriate 
management of gout to ensure uniformity in 
their care standards. They should be aware of 
the comorbidities associated with gout, such 
as cardiovascular and renal diseases. A sound 
understanding of the comorbidities may 
motivate GPs and patients to achieve good 
control of patients’ condition.  
Although guidelines are readily available and 
medications have been in use for decades, it is 
a challenge to maintain high standards in the 
management of gout. In addition, clinicians 
should be able to identify the risk factors and 
comorbidities which may predispose one to 
gout flares, such as obesity, and plan their 
management strategies around these.5 
However, the presence of these comorbidities 
can also make management difficult and may 
implicate the efficacy of pharmacological 
therapy. With these recommendations in hand, 
it would help the practice to meet the 
standards set by the guidelines and also 
provide optimum care for gout patients in the 
future. 
 
 
Learning Points 
What is known already 
 Gout is a common occurrence in primary care and its incidence has been rising, affecting 
mainly males and those over 65 years of age.  
 If not managed appropriately, gout may contribute to renal and cardiovascular 
comorbidities and may cause permanent joint destruction.  
 Conservative treatments (i.e. lifestyle modifications) in combination with medical therapy 
(i.e. NSAIDs, colchicines and corticosteroids) have been the mainstay of gout 
management.  
 Allopurinol is commonly used as a prophylactic medication to reduce recurrent attacks. 
What this study adds 
 The BSR has released a set of guidelines to direct the appropriate management of gout. 
However, we suspect that these are not being adhered to closely across primary care.  
 Patients on allopurinol should have their dosages reviewed in line with their sUA levels. 
However, determining the optimal dose to prescribe to achieve good control of sUA 
levels is challenging.  
 Clearly there needs to be improvements in adherence to guidelines, especially in the area 
of monitoring sUA levels, follow-up and prescribing allopurinol where clinically indicated. 
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